Contributions
Abstract: EP1422
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Background: Disease burden/progression in people with Multiple Sclerosis (PwMS) is traditionally measured by reported relapse, EDSS and MRI change. Multiple Sclerosis Impact Scale (MSIS-29) is a patient reported outcome (PRO) that provides patient perspective about disease impact globally, as well as by subscale (physical, cognitive). PwMS frequently experience cognitive impairment but measurements of cognitive impact are not commonly included in routine care. If cognitive impact is usually measured through unidimensional outcome measures, such as SDMT. Use of a multi-domain screening cognitive assessment battery (NeuroTrax, CAB-NT) provides rich quantitative patient centric information. The relationship of the MSIS-29 and CAB-NT in PwMS has not been explored.
Objective: To examine the relationship in PwMS between MSIS-29 scores with CAB-NT outcome measures
Methods: Retrospective cross-sectional review of PwMS who completed both MSIS-29 and CAB-NT in routine care. MSIS-29 scores included: global score, and physical and cognitive sub-scores. CAB-NT included 7 cognitive domains global cognitive summary score (GCS), memory (Mem), executive function (Exe), attention (Att), information processing speed (Inf), verbal function (Ver) and motor skills (Mot). Multivariate regression analysis was used to analyze these potential relationships. Significance was set at p< 0.05.
Results: 244 PwMS, average age 50 +/- 11.7, 47% female. Significant relationships were identified: MSIS-29 global scores and GCS (r=0.34, p< 0.05), Mem (r=0.19, p< 0.05), Exe (r=0.38, p< 0.05), Att (r=0.26, p< 0.05), Inf (r=0.22, p< 0.05), Ver (r=0.21, p< 0.05), and Mot (r=0.37, p< 0.05); MSIS-29 physical score and GCS (r=0.36, p< 0.05), Mem (r=0.20, p< 0.05), Exe (r=0.41, p< 0.05), Att (r=0.29, p< 0.05), Inf (r=0.22, p< 0.05), Vis (r=0.15, p< 0.05), Ver (r=0.23, p< 0.05), and Mot (r=0.39, p< 0.05): MSIS-29 cognitive score and GCS (r=0.26, p< 0.05), Mem (r=0.16, p< 0.05), Exe (r=0.30, p< 0.05), Att (r=0.23, p< 0.05), Inf (r=0.21, p< 0.05), Ver (r=0.18, p< 0.05), and Mot (r=0.30, p< 0.05).
Conclusions: Self-reported MSIS-29 scores, whether reflecting global or physical or cognitive sub-scores are related to individual cognitive domain scores in PwMS. Perception of disease impact in PwMS must be related to objective analysis of disease impact to better understand both their perceptions and the basis of these perceptions so that appropriate/effective treatment choices/changes can be made.
Disclosure: (This study was not supported by outside funds):
KC- Nothing to disclose
MG- Research support (Biogen, EMD Serono, Novartis, Sanofi, Teva); speaker fees/consultant (Acorda, Amgen, Biogen, EMD Serono, Medtronic, Novartis, Sanofi, Saol Therapeutics, Teva).
JS- Nothing to disclose
AG- Nothing to disclose
MZ- Speaker fees (Acorda, Biogen, Genzyme and Teva)
BB- Speaker fees (Biogen, Genotech, Genzyme and Teva).
MB: Nothing to disclose
LF- Nothing to disclose
DG- Nothing to disclose
CS- Nothing to disclose
JW- Nothing to disclose
Abstract: EP1422
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Background: Disease burden/progression in people with Multiple Sclerosis (PwMS) is traditionally measured by reported relapse, EDSS and MRI change. Multiple Sclerosis Impact Scale (MSIS-29) is a patient reported outcome (PRO) that provides patient perspective about disease impact globally, as well as by subscale (physical, cognitive). PwMS frequently experience cognitive impairment but measurements of cognitive impact are not commonly included in routine care. If cognitive impact is usually measured through unidimensional outcome measures, such as SDMT. Use of a multi-domain screening cognitive assessment battery (NeuroTrax, CAB-NT) provides rich quantitative patient centric information. The relationship of the MSIS-29 and CAB-NT in PwMS has not been explored.
Objective: To examine the relationship in PwMS between MSIS-29 scores with CAB-NT outcome measures
Methods: Retrospective cross-sectional review of PwMS who completed both MSIS-29 and CAB-NT in routine care. MSIS-29 scores included: global score, and physical and cognitive sub-scores. CAB-NT included 7 cognitive domains global cognitive summary score (GCS), memory (Mem), executive function (Exe), attention (Att), information processing speed (Inf), verbal function (Ver) and motor skills (Mot). Multivariate regression analysis was used to analyze these potential relationships. Significance was set at p< 0.05.
Results: 244 PwMS, average age 50 +/- 11.7, 47% female. Significant relationships were identified: MSIS-29 global scores and GCS (r=0.34, p< 0.05), Mem (r=0.19, p< 0.05), Exe (r=0.38, p< 0.05), Att (r=0.26, p< 0.05), Inf (r=0.22, p< 0.05), Ver (r=0.21, p< 0.05), and Mot (r=0.37, p< 0.05); MSIS-29 physical score and GCS (r=0.36, p< 0.05), Mem (r=0.20, p< 0.05), Exe (r=0.41, p< 0.05), Att (r=0.29, p< 0.05), Inf (r=0.22, p< 0.05), Vis (r=0.15, p< 0.05), Ver (r=0.23, p< 0.05), and Mot (r=0.39, p< 0.05): MSIS-29 cognitive score and GCS (r=0.26, p< 0.05), Mem (r=0.16, p< 0.05), Exe (r=0.30, p< 0.05), Att (r=0.23, p< 0.05), Inf (r=0.21, p< 0.05), Ver (r=0.18, p< 0.05), and Mot (r=0.30, p< 0.05).
Conclusions: Self-reported MSIS-29 scores, whether reflecting global or physical or cognitive sub-scores are related to individual cognitive domain scores in PwMS. Perception of disease impact in PwMS must be related to objective analysis of disease impact to better understand both their perceptions and the basis of these perceptions so that appropriate/effective treatment choices/changes can be made.
Disclosure: (This study was not supported by outside funds):
KC- Nothing to disclose
MG- Research support (Biogen, EMD Serono, Novartis, Sanofi, Teva); speaker fees/consultant (Acorda, Amgen, Biogen, EMD Serono, Medtronic, Novartis, Sanofi, Saol Therapeutics, Teva).
JS- Nothing to disclose
AG- Nothing to disclose
MZ- Speaker fees (Acorda, Biogen, Genzyme and Teva)
BB- Speaker fees (Biogen, Genotech, Genzyme and Teva).
MB: Nothing to disclose
LF- Nothing to disclose
DG- Nothing to disclose
CS- Nothing to disclose
JW- Nothing to disclose